STRO
Sutro Biopharma, Inc. (STRO) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
R&D intensity of 3.17% of revenue suggests a relatively innovation-oriented footprint, but peers with cleaner product mixes typically disclose stronger environmental transition benefits.
No direct emissions, energy, or waste metrics were provided, limiting evidence of environmental leadership versus peers in a sector where operational footprint is often material.
The absence of disclosed environmental targets or climate-risk metrics weakens comparability, because peers with formal transition plans usually demonstrate clearer regulatory preparedness.
High gross margin can support investment in cleaner processes, yet without environmental disclosures it does not establish a stronger ESG position than peers.
Social
Stock-based compensation at 14.83% of revenue indicates meaningful employee alignment, but peers with lower dilution and broader retention metrics often show stronger workforce stewardship.
No workforce safety, turnover, diversity, or customer-impact data were provided, which constrains assessment against peers on the most material social indicators.
The lack of disclosed human-capital policies reduces visibility on labor practices, while better-disclosing peers typically demonstrate more robust social governance.
Capital discipline appears adequate, but without community, product-responsibility, or supply-chain metrics, the social profile remains mid-pack versus peers.
Governance
Net debt to EBITDA of 0.32x suggests conservative leverage, which generally supports governance resilience versus more highly levered peers.
A negative debt-to-equity ratio likely reflects balance-sheet structure rather than strength, so it does not materially improve governance standing versus peers.
Stock-based compensation of 14.83% of revenue may indicate incentive alignment, but peers with lower compensation intensity often face less dilution-related governance scrutiny.
No board, audit, ownership, or controversy data were provided, limiting evidence of stronger governance than peers despite acceptable capital structure.
Overall Score
STRO appears mid-pack versus peers because conservative leverage and meaningful R&D support ESG resilience, but limited disclosure prevents evidence of stronger leadership.
Score Driver: Limited ESG Disclosure Relative To Peers
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Sutro Biopharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
